search
Back to results

A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

Primary Purpose

COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome

Status
Recruiting
Phase
Phase 1
Locations
Brazil
Study Type
Interventional
Intervention
EOM613
Sponsored by
EOM Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for COVID-19 Pneumonia focused on measuring Cytokines, Chemokines, COVID-19, SARS-CoV-2, Immune modulation

Eligibility Criteria

18 Years - 84 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

  1. Inclusion Criteria

    1. Non-ICU cohort:

      • Males or females ≥18 years and < 85 years of age
      • Positive test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) by nasopharyngeal sampling using a reliable nucleic acid Reverse Transcription-Polymerase Chain Reaction (RT-PCR) assay or fast serological tests confirmed by RT PCR afterward
      • Hospitalized for Acute Respiratory Distress Syndrome (ARDS) or pneumonia
      • Requires oxygen therapy by nasal catheter or mask, but not invasive mechanical ventilation at the enrollment

    2. ICU cohort:

      • Males or females ≥18 years and < 85 years of age
      • Positive test for SARS-CoV-2 by nasopharyngeal sampling using a reliable nucleic acid RT-PCR assay
      • Hospitalized for ARDS or pneumonia and requires invasive mechanical ventilation at enrollment

    3. Both cohorts:

      • Participant or suitable proxy able to provide written informed consent before study procedures are performed
      • Able to adhere to the study schedule and other protocol requirements
      • No known contraindications for administering EOM613, including Mycobacterium tuberculosis infection (assessed by the anamnesis) or receiving immunosuppressant therapy after transplant
      • Not enrolled in another study of an investigational agent during this study
      • Patients who developed complications of COVID-19 (such as myocardial disease, kidney dysfunction, clotting disorder, encephalitis, severe fatigue, or multi-immune inflammatory syndrome) are eligible

  2. Exclusion Criteria

    1. Both cohorts:

      • Active participation in any other clinical trial of an experimental treatment for COVID-19
      • Participation in another clinical trial with any investigational new drug within 12 months before enrollment, except if there is a possible benefit to the participant in the investigator's opinion (According to the Brazilian Resolution CNS 251/97 II.2-J)
      • Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 is prohibited <24 hours before study medication initiation
      • Sequential Organ Failure Assessment Score >10
      • Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated Glomerular Filtration Rate [eGFR] <30)
      • Active cancer receiving any therapeutic intervention or under palliative care

    2. Both cohorts, conditions existing before COVID-19:

      • Chronic Obstructive Pulmonary Disease (COPD)
      • Heart failure or cardiomyopathies
      • Sickle cell disease
      • Solid-organ transplantation
      • Uncontrolled or poorly controlled Type 2 diabetes mellitus
      • Immunodeficiency or immunosuppressive therapy
      • Pregnant or breastfeeding
      • Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment
      • Known active Mycobacterium tuberculosis infection (assessed by the anamnesis)
      • Patients who are unwilling or unable to follow protocol requirements
      • Patients with body mass index (BMI) < 18 kg/m2 or > 40 kg/m2

Sites / Locations

  • Oswaldo CruzRecruiting
  • Hospital de AmorRecruiting
  • Hospital Municipal de BarueriRecruiting
  • Casa De SaúdeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

non-ICU hospitalized

ICU hospitalized

Arm Description

Patients who are hospitalized at study enrollment but are not being treated in the ICU

Patients who, at study enrollment, are being treated in the hospital ICU

Outcomes

Primary Outcome Measures

Change from baseline to day 11 in mean blood urea nitrogen (BUN) level.
The BUN primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (BUN is also assessed on days 2, 5, and 8). BUN is obtained from a venous blood draw and measured in millimoles of urea per liter. 2.1 to 8.5 mmol/L is considered normal; values above 8.5 mmol/L may indicate renal impairment.
Change from baseline to day 11 in mean blood creatinine level.
The blood creatinine primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (blood creatinine is also assessed on days 2, 5, and 8). Blood creatinine is obtained from a venous blood draw and measured in micromoles of creatinine per liter. 65.4 to 119.3 micromoles/L in adult women and 52.2 to 91.9 micromoles/L in adult men are considered normal; values above these ranges may indicate renal impairment.
Change from baseline to day 11 in mean blood lymphocyte count.
The blood lymphocyte count primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (blood lymphocyte count is also assessed on days 2, 5, and 8). Blood lymphocyte count is obtained from a venous blood draw and measured as the number of lymphocytes per microliter of blood. Between 1,000 and 3000 lymphocytes per microliter of blood is considered normal. Values below this range have correlated with the severity of COVID-19 infection; values above this range can be indicative of an infection, cancer of the blood or lymphatic system, or an autoimmune disorder.
Change from baseline to day 11 in mean serum soluble interleukin-2 receptor (sIL-2R) level.
The serum sIL-2R primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (serum sIL-2R will also be assessed on days 2, 5, 8, 14 and 28). Serum sIL-2R levels are measured with a Quantitative Multiplex Bead Assay. The normal range has been reported as 175.3 - 858.2 pg/mL. Elevated levels are found in individuals with severe inflammatory conditions and solid tumors.
Change from baseline to day 11 in mean serum interleukin-6 (IL-6).
The serum IL-6 primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (serum IL-6 will also be assessed on days 2, 5, 8, 14 and 28). Serum IL-6 levels are measured with a Quantitative Multiplex Bead Assay. Normal values have been reported as <2.0 pg/mL. Elevated levels are associated with inflammatory conditions and predict lower chances of survival in COVID-19 patients.
Change from baseline to day 11 in mean serum interleukin-10 (IL-10) levels.
The serum IL-10 primary outcome measure is its change from baseline to day 11 or discharge, whichever comes first (serum IL-10 will also be assessed on days 2, 5, 8, 14 and 28). Serum IL-10 levels are measured with a Quantitative Multiplex Bead Assay. Normal values have been reported as <2.8 pg/mL. Elevated levels are associated with inflammatory conditions and predict lower chances of survival in COVID-19 patients.

Secondary Outcome Measures

Median change from baseline to day 56 in World Health Organization (WHO) Scale Assessment of COVID-19 Symptom Severity
The WHO Scale secondary outcome measure is the median change from baseline to day 56. This ordinal Scale is from 0 (no clinical/virological evidence of infection) to 8 (death). Scale assessments are made on patients on days 1-14, 21, 28, 42 and 56. Scale assessments of discharged patients are made during a home visit by a study nurse.
Percent of hospital days with ventilator and/or oxygen use, and percent of hospital days with maximum ventilator pressure and maximum oxygen use
Daily recording of ventilator and oxygen use (on or off), ventilator pressure, and oxygen use (percent and flow rate) in the morning and evening for patients requiring respiratory assistance. These data will be used to calculate the mean percent of total hospital days with ventilator and/or oxygen use, and the mean percent of days of maximum ventilator pressure and maximum oxygen use from day 1 of ventilator and/or oxygen use to subsequent days.

Full Information

First Posted
August 25, 2021
Last Updated
January 27, 2022
Sponsor
EOM Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT05212532
Brief Title
A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
Official Title
A Proof-of-Concept Study Evaluating Safety, Tolerability, and Preliminary Efficacy of EOM613 in COVID-19 Infected Patients With Severe Symptoms
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 9, 2021 (Actual)
Primary Completion Date
February 28, 2022 (Anticipated)
Study Completion Date
March 30, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
EOM Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of EOM613 in this patient population.
Detailed Description
Much of the morbidity and mortality in COVID-19 infection is thought to be the result of an overly zealous attack by the immune system (e.g., cytokine storm and IL-6 elevations) as it attempts to counteract the viral infection. Some drugs with immunomodulatory effects (e.g., dexamethasone, tocilizumab) have been shown to reduce virus-induced cytokine storms and key pro-inflammatory cytokines, including IL-6. EOM613 is a peptide nucleic acid with novel immune-modulating properties, including modulation of IL-6 expression. It has an excellent safety profile and has yielded promising therapeutic results in patients with Acquired Immunodeficiency Syndrome (AIDS), cancer cachexia and severe rheumatoid arthritis. EOM613 was reported to have antiviral activity in cell cultures inoculated with Human Immunodeficiency Virus (HIV) or adenovirus. This proof-of-concept study is the first clinical trial of EOM613 in patients with COVID-19 infection. This study will include two cohorts of hospitalized patients, non-ICU and ICU. In non-ICU patients, EOM613 is to be administered subcutaneously (SC) at a dose of 2 mL once daily (QD) for 10 days, for a total of 20 mL. In ICU patients, EOM613 is to be administered SC at a dose of 2 mL twice daily (BID) for 5 days followed by 2 mL QD for 5 days, for a total of 30 mL. The primary objective and outcome measures include assessment of safety and tolerability of EOM613, based on clinical laboratory, physical exams, and assessment of adverse events (AEs). The secondary objectives and outcome measures are 1) The proportions of non-ICU patients discharged with and without progression to invasive mechanical ventilation or ICU; 2) The proportion of ICU patients who die, are discharged to the infirmary, or discharged from the hospital; and 3) Assessment of levels of pro- and anti-inflammatory cytokines in Cytokine Panel 13, and their correlations with primary and secondary endpoints.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
Keywords
Cytokines, Chemokines, COVID-19, SARS-CoV-2, Immune modulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Open label study will include 2 cohorts, non-ICU hospitalized and ICU hospitalized patients
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
non-ICU hospitalized
Arm Type
Experimental
Arm Description
Patients who are hospitalized at study enrollment but are not being treated in the ICU
Arm Title
ICU hospitalized
Arm Type
Experimental
Arm Description
Patients who, at study enrollment, are being treated in the hospital ICU
Intervention Type
Drug
Intervention Name(s)
EOM613
Intervention Description
peptide nucleic acid (PNA)
Primary Outcome Measure Information:
Title
Change from baseline to day 11 in mean blood urea nitrogen (BUN) level.
Description
The BUN primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (BUN is also assessed on days 2, 5, and 8). BUN is obtained from a venous blood draw and measured in millimoles of urea per liter. 2.1 to 8.5 mmol/L is considered normal; values above 8.5 mmol/L may indicate renal impairment.
Time Frame
Baseline and day 11 or discharge, whichever comes first.
Title
Change from baseline to day 11 in mean blood creatinine level.
Description
The blood creatinine primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (blood creatinine is also assessed on days 2, 5, and 8). Blood creatinine is obtained from a venous blood draw and measured in micromoles of creatinine per liter. 65.4 to 119.3 micromoles/L in adult women and 52.2 to 91.9 micromoles/L in adult men are considered normal; values above these ranges may indicate renal impairment.
Time Frame
Baseline and day 11 or discharge, whichever comes first.
Title
Change from baseline to day 11 in mean blood lymphocyte count.
Description
The blood lymphocyte count primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (blood lymphocyte count is also assessed on days 2, 5, and 8). Blood lymphocyte count is obtained from a venous blood draw and measured as the number of lymphocytes per microliter of blood. Between 1,000 and 3000 lymphocytes per microliter of blood is considered normal. Values below this range have correlated with the severity of COVID-19 infection; values above this range can be indicative of an infection, cancer of the blood or lymphatic system, or an autoimmune disorder.
Time Frame
Baseline and day 11 or discharge, whichever comes first.
Title
Change from baseline to day 11 in mean serum soluble interleukin-2 receptor (sIL-2R) level.
Description
The serum sIL-2R primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (serum sIL-2R will also be assessed on days 2, 5, 8, 14 and 28). Serum sIL-2R levels are measured with a Quantitative Multiplex Bead Assay. The normal range has been reported as 175.3 - 858.2 pg/mL. Elevated levels are found in individuals with severe inflammatory conditions and solid tumors.
Time Frame
Baseline and day 11 or discharge, whichever comes first.
Title
Change from baseline to day 11 in mean serum interleukin-6 (IL-6).
Description
The serum IL-6 primary outcome measure is its change from baseline to day 11 or to discharge, whichever comes first (serum IL-6 will also be assessed on days 2, 5, 8, 14 and 28). Serum IL-6 levels are measured with a Quantitative Multiplex Bead Assay. Normal values have been reported as <2.0 pg/mL. Elevated levels are associated with inflammatory conditions and predict lower chances of survival in COVID-19 patients.
Time Frame
Baseline and day 11 or discharge, whichever comes first.
Title
Change from baseline to day 11 in mean serum interleukin-10 (IL-10) levels.
Description
The serum IL-10 primary outcome measure is its change from baseline to day 11 or discharge, whichever comes first (serum IL-10 will also be assessed on days 2, 5, 8, 14 and 28). Serum IL-10 levels are measured with a Quantitative Multiplex Bead Assay. Normal values have been reported as <2.8 pg/mL. Elevated levels are associated with inflammatory conditions and predict lower chances of survival in COVID-19 patients.
Time Frame
Baseline and day 11 or discharge, whichever comes first.
Secondary Outcome Measure Information:
Title
Median change from baseline to day 56 in World Health Organization (WHO) Scale Assessment of COVID-19 Symptom Severity
Description
The WHO Scale secondary outcome measure is the median change from baseline to day 56. This ordinal Scale is from 0 (no clinical/virological evidence of infection) to 8 (death). Scale assessments are made on patients on days 1-14, 21, 28, 42 and 56. Scale assessments of discharged patients are made during a home visit by a study nurse.
Time Frame
Baseline and day 56 or death, whichever comes first
Title
Percent of hospital days with ventilator and/or oxygen use, and percent of hospital days with maximum ventilator pressure and maximum oxygen use
Description
Daily recording of ventilator and oxygen use (on or off), ventilator pressure, and oxygen use (percent and flow rate) in the morning and evening for patients requiring respiratory assistance. These data will be used to calculate the mean percent of total hospital days with ventilator and/or oxygen use, and the mean percent of days of maximum ventilator pressure and maximum oxygen use from day 1 of ventilator and/or oxygen use to subsequent days.
Time Frame
Day 1 (baseline) of ventilator and/or oxygen use until ventilator and/or oxygen use is discontinued

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
84 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Non-ICU cohort: Males or females ≥18 years and < 85 years of age Positive test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) by nasopharyngeal sampling using a reliable nucleic acid Reverse Transcription-Polymerase Chain Reaction (RT-PCR) assay or fast serological tests confirmed by RT PCR afterward Hospitalized for Acute Respiratory Distress Syndrome (ARDS) or pneumonia Requires oxygen therapy by nasal catheter or mask, but not invasive mechanical ventilation at the enrollment ICU cohort: Males or females ≥18 years and < 85 years of age Positive test for SARS-CoV-2 by nasopharyngeal sampling using a reliable nucleic acid RT-PCR assay Hospitalized for ARDS or pneumonia and requires invasive mechanical ventilation at enrollment Both cohorts: Participant or suitable proxy able to provide written informed consent before study procedures are performed Able to adhere to the study schedule and other protocol requirements No known contraindications for administering EOM613, including Mycobacterium tuberculosis infection (assessed by the anamnesis) or receiving immunosuppressant therapy after transplant Not enrolled in another study of an investigational agent during this study Patients who developed complications of COVID-19 (such as myocardial disease, kidney dysfunction, clotting disorder, encephalitis, severe fatigue, or multi-immune inflammatory syndrome) are eligible Exclusion Criteria Both cohorts: Active participation in any other clinical trial of an experimental treatment for COVID-19 Participation in another clinical trial with any investigational new drug within 12 months before enrollment, except if there is a possible benefit to the participant in the investigator's opinion (According to the Brazilian Resolution CNS 251/97 II.2-J) Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 is prohibited <24 hours before study medication initiation Sequential Organ Failure Assessment Score >10 Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated Glomerular Filtration Rate [eGFR] <30) Active cancer receiving any therapeutic intervention or under palliative care Both cohorts, conditions existing before COVID-19: Chronic Obstructive Pulmonary Disease (COPD) Heart failure or cardiomyopathies Sickle cell disease Solid-organ transplantation Uncontrolled or poorly controlled Type 2 diabetes mellitus Immunodeficiency or immunosuppressive therapy Pregnant or breastfeeding Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment Known active Mycobacterium tuberculosis infection (assessed by the anamnesis) Patients who are unwilling or unable to follow protocol requirements Patients with body mass index (BMI) < 18 kg/m2 or > 40 kg/m2
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Melina Szkelnik-Sidi, BS
Phone
+ 55 11 98258-6261
Email
melina.sidi@azidusbrasil.com.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Irach Taraporewala, PhD
Organizational Affiliation
CEO and Director, EOM Pharma
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Frank L Douglas, PhD, MD
Organizational Affiliation
Scientific Advisor & Chair of Scientific Advisory Board, EOM Pharma
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Florentino Cardoso Filho, MD, PhD
Organizational Affiliation
Physician, Casa de Saude Hospital, Campinas, SP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Oswaldo Cruz
City
Manguinhos
State/Province
Rio De Janeiro
ZIP/Postal Code
21040-900
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elie Fiss, MD, PhD
Phone
0xx21)2598-4242
Email
eliefiss@uol.com.br
First Name & Middle Initial & Last Name & Degree
Evelyn Cristina C Da Silva
Phone
0xx21)2598-4242
Email
eccsilva@haoc.com.br
First Name & Middle Initial & Last Name & Degree
Elie Fiss, MD, PhD
Facility Name
Hospital de Amor
City
Barretos
State/Province
São Paulo
ZIP/Postal Code
14784-400
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
César Maurício, MD
Email
cesarms.research@gmail.com
First Name & Middle Initial & Last Name & Degree
Letícia Barbieri
Email
barbieri.pesquisaclinica@hcancerbarretos.com.br
First Name & Middle Initial & Last Name & Degree
César Maurício, MD
Facility Name
Hospital Municipal de Barueri
City
Barueri
State/Province
São Paulo
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paulo Tierno
Email
paulo.tierno@hmb.spdm.org.br
First Name & Middle Initial & Last Name & Degree
Marielle Nunes
Email
sc@brtrials.com.br
First Name & Middle Initial & Last Name & Degree
Paulo Tierno, MD
Facility Name
Casa De Saúde
City
Boqueirão
State/Province
São Paulo
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florentino Cardoso Filho, MD, PhD
Phone
+55 19 991232882
Email
florentino.cardoso@hospitalcare.com.br
First Name & Middle Initial & Last Name & Degree
Jomenica do Livramento
Phone
13 3202 2500
Email
jomenica@casadesaudecampinas.com.br
First Name & Middle Initial & Last Name & Degree
Florentino Cardoso Filho, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
Citation
Advanced Viral Research Corp. (ADVR). ADVR reports AVR118 inhibits inflammatory arthritis in animal model and in rheumatoid arthritis patients in human clinical trial. ADVR press release, PR Newswire, December 3, 2003.
Results Reference
background
Citation
Chasen M, Bhargava R, Hirschman SZ, Taraporewala I. Phase II study of OHR/AVR118 in anorexia- cachexia. Abstract of poster presentation at the 7th Cachexia conference, Kobe/Osaka, Japan, December 9-11, 2013. J Cachexia Sarcopenia Muscle 2013;4(4):335-6.
Results Reference
background
PubMed Identifier
21194662
Citation
Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc. 2011 Jan;12(1):62-7. doi: 10.1016/j.jamda.2010.02.012. Epub 2010 May 15.
Results Reference
background
Citation
COVID-19 Treatment Guidelines, Interleukin-6 Inhibitors. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/. Updated April 21, 2021. Accessed August 24, 2021.
Results Reference
background
PubMed Identifier
23719681
Citation
Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013 Oct;52(10):855-68. doi: 10.1007/s40262-013-0079-0.
Results Reference
background
Citation
D'Olimpio JT, Chasen MR, Sharma R, Diego M, Gullo V, MacDonald N. Phase II study of AVR118 in the management of cancer-related anorexia/cachexia. Doi: 10.1200/jco.2009.27.15_suppl.e20631 (abstract presentation). Journal of Clinical Oncology 2009; 27, No. 15_suppl., e20631-e20631.
Results Reference
background
Citation
D'Olimpio JT, Hirschman SZ, Shtemer Z, Didiego M. Anti-cachectic effects of a novel peptide nucleic acid: Preliminary results of a phase I/II clinical trial. Doi: 10.1200/jco.2004.22.90140.8087 (abstract presentation). Journal of Clinical Oncology. July 15, 2004; 22, no. 14_suppl 8087-8087.
Results Reference
background
PubMed Identifier
1724467
Citation
Friedland B. In vitro antiviral activity of a peptide-nucleic acid solution against the human immunodeficiency virus and influenza A virus. J R Soc Health. 1991 Oct;111(5):170-1. doi: 10.1177/146642409111100505.
Results Reference
background
PubMed Identifier
8795297
Citation
Hirschman SZ, Chen CW. Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus. J Investig Med. 1996 Aug;44(6):347-51.
Results Reference
background
Citation
Hirschman SZ. Activation of human monocytes/macrophages by OHR/AVR118 promotes both pro-and anti-inflammatory phenotypes. Available: https://www.scirp.org/journal/PaperInformation.aspx?paperID=42617. Accessed August 24, 2021. Adv Bioscience Biotechnology. 2014, 5:161-168.
Results Reference
background
PubMed Identifier
33014208
Citation
Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, Hirano T. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020 Oct 1;40:37. doi: 10.1186/s41232-020-00146-3. eCollection 2020.
Results Reference
background
PubMed Identifier
11064099
Citation
Lazzarino DA, Diego M, Musi E, Hirschman SZ, Alexander RJ. CXCR4 and CCR5 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator. Immunol Lett. 2000 Nov 1;74(3):189-95. doi: 10.1016/s0165-2478(00)00258-3.
Results Reference
background
PubMed Identifier
11448124
Citation
Lazzarino DA, de Diego M, Hirschman SZ, Zhang KY, Shaikh S, Musi E, Liaw L, Alexander RJ. IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes. Cytokine. 2001 May 21;14(4):234-9. doi: 10.1006/cyto.2001.0867.
Results Reference
background
PubMed Identifier
12187500
Citation
Levett PN, Hirschman SZ, Roach TC, Broome H, Alexander RJ, Fraser HS. Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV. HIV Clin Trials. 2002 Jul-Aug;3(4):272-8. doi: 10.1310/N34A-653T-ABF5-8Q1R.
Results Reference
background
PubMed Identifier
32758889
Citation
Scherger S, Henao-Martinez A, Franco-Paredes C, Shapiro L. Rethinking interleukin-6 blockade for treatment of COVID-19. Med Hypotheses. 2020 Nov;144:110053. doi: 10.1016/j.mehy.2020.110053. Epub 2020 Jun 27.
Results Reference
background
Citation
Alexander R.J., Meyer K.A., Camposano E., Lazzarino D.A., De Diego M. Product R induces differentiation of the human myelocytic leukemia cell line HL-60. American Association for Cancer Research Special Conference (Proteases, Extracellular Matrix and Cancer). Hilton Head Island, SC, USA, 2002.
Results Reference
background

Learn more about this trial

A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms

We'll reach out to this number within 24 hrs